<DOC>
	<DOCNO>NCT02695082</DOCNO>
	<brief_summary>To compare , insulin use index date , incidence hospitalization acute kidney injury ( AKI ) among patient type 2 diabetes mellitus new user dapagliflozin new user antidiabetic drug ( ADs ) class sodium-glucose cotransporter 2 ( SGLT2 ) inhibitor , insulin monotherapy , metformin monotherapy , sulfonylurea monotherapy .</brief_summary>
	<brief_title>Acute Kidney Injury Patients Dapagliflozin Other Antidiabetic Medications</brief_title>
	<detailed_description>The overall goal research study estimate risk hospitalization acute kidney injury patient prescribe dapagliflozin compare patient prescribe specific oral antidiabetic drug . Dapagliflozin antidiabetic drug use treat type 2 diabetes mellitus . Because mechanism action dapagliflozin result small safety monitoring study , interest evaluate safety dapagliflozin large population . The study implement three administrative health care data source two country : United Kingdom , Clinical Practice Research Datalink ( CPRD ) ; United States , Centers Medicare Medicaid Services ( CMS ) Medicare databases HealthCore Integrated Research Database ( HIRDSM ) . Individuals database include study meet follow age criterion ; 18 year old ( CPRD HIRD ) , 65 year old ( Medicare ) ; type 1 diabetes , new user one study drug meet criterion least 180 day electronic data first prescription study drug . The study period start July 1 , 2013 CPRD , January 1 , 2014 PHARMO January 9 , 2014 United States data source , end late available data database time analysis .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>1. receive newly prescribe dapagliflozin ( without ADs ) receive newly prescribe AD ( without ADs ) class SGLT2 inhibitor , insulin monotherapy , metformin monotherapy , sulfonylurea monotherapy ; 2. diagnostic code indicate type1 diabetes ; 3. age 18 year old index date CPRD patient , 1864 year HIRDSM patient , 65 year old Medicarepatients ; 4. enrol data source least 180 day first prescription dispense dapagliflozin eligible index comparator AD previous diagnosis chronic kidney failure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>